RCT: Daratumumab, lenalidomide, and dexamethasone vs. lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma.

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial – The Lancet Oncology

Commentary: Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma – The ASCO Post